To the Editor Prostate cancer screening is currently not recommended in the UK.1 In their recent cohort study in JAMA Oncology, Eldred-Evans and colleagues2 make an interesting case for using imaging with different cutoff points to potentially try to improve sensitivity and specificity compared with prostate-specific antigen screening. With no confirmatory biopsies from the patients with negative screening results, it is difficult to ascertain how accurate any of these modalities are; however, a reasonable estimate can be derived.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Oong Z, Parikh O. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography—The IP1-PROSTAGRAM Study. JAMA Oncol. 2021;7(10):1575. doi:10.1001/jamaoncol.2021.2964
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.